CA3140055A1 - Nk cell-directed chimeric proteins - Google Patents

Nk cell-directed chimeric proteins Download PDF

Info

Publication number
CA3140055A1
CA3140055A1 CA3140055A CA3140055A CA3140055A1 CA 3140055 A1 CA3140055 A1 CA 3140055A1 CA 3140055 A CA3140055 A CA 3140055A CA 3140055 A CA3140055 A CA 3140055A CA 3140055 A1 CA3140055 A1 CA 3140055A1
Authority
CA
Canada
Prior art keywords
chimeric protein
domain
nkg2a
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140055A
Other languages
English (en)
French (fr)
Inventor
Taylor Schreiber
Casey SHUPTRINE
George FROMM
Suresh DE SILVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of CA3140055A1 publication Critical patent/CA3140055A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3140055A 2019-05-16 2020-05-15 Nk cell-directed chimeric proteins Pending CA3140055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848915P 2019-05-16 2019-05-16
US62/848,915 2019-05-16
PCT/US2020/033169 WO2020232365A1 (en) 2019-05-16 2020-05-15 Nk cell-directed chimeric proteins

Publications (1)

Publication Number Publication Date
CA3140055A1 true CA3140055A1 (en) 2020-11-19

Family

ID=73289381

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140055A Pending CA3140055A1 (en) 2019-05-16 2020-05-15 Nk cell-directed chimeric proteins

Country Status (7)

Country Link
US (2) US20200399344A1 (https=)
EP (1) EP3969058A4 (https=)
JP (1) JP2022532430A (https=)
CN (1) CN114126663A (https=)
AU (1) AU2020276296A1 (https=)
CA (1) CA3140055A1 (https=)
WO (1) WO2020232365A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024524301A (ja) * 2021-07-02 2024-07-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用
CN114853905B (zh) * 2022-04-14 2022-11-22 呈诺再生医学科技(珠海横琴新区)有限公司 一种基因修饰nk细胞与抗体联合使用治疗肿瘤方案
WO2024073513A2 (en) * 2022-09-27 2024-04-04 Affini-T Therapeutics, Inc. Chimeric receptors comprising interleukin 7 receptor (il7r) domains
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2035452B1 (en) * 2006-06-22 2012-04-25 Novo Nordisk A/S Soluble heterodimeric receptors and uses thereof
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
JP6981973B2 (ja) * 2015-10-01 2021-12-17 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
BR112019005964A2 (pt) * 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras

Also Published As

Publication number Publication date
EP3969058A1 (en) 2022-03-23
CN114126663A (zh) 2022-03-01
US20200399344A1 (en) 2020-12-24
JP2022532430A (ja) 2022-07-14
EP3969058A4 (en) 2023-06-28
US20230045794A1 (en) 2023-02-16
WO2020232365A1 (en) 2020-11-19
AU2020276296A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
JP7260477B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
US20230045794A1 (en) Nk cell-directed chimeric proteins
CN116063567A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
JP7121029B2 (ja) Ｃｓｆ１ｒベースのキメラタンパク質
US20210379153A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
US20200071380A1 (en) Combination therapies comprising sirp alpha-based chimeric proteins
JP7244428B2 (ja) Ｖｓｉｇ８ベースのキメラタンパク質
CN112888711A (zh) 基于flt3l的嵌合蛋白
US20240141014A1 (en) Mutant pd-1 extracellular domains
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
WO2022187583A1 (en) Combination therapies with tim-3-based chimeric proteins
BR112021003683A2 (pt) terapias de combinação
US20210179689A1 (en) Combination therapies comprising tim-3-based chimeric proteins
RU2792239C2 (ru) Химерные белки на основе csf1r
HK40019689A (en) Vsig8-based chimeric proteins
HK40019689B (en) Vsig8-based chimeric proteins

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251201

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260202